Filing Flows › Arcutis Biotherapeutics (ARQT) › ZORYVE cream 0.15% revenue
Arcutis Biotherapeutics (ARQT) ZORYVE cream 0.15% revenue by quarter
Arcutis Biotherapeutics' ZORYVE cream 0.15% revenue was $27.3M in Q3 2026 (third quarter 2026), +13% from Q2 2026. Over the last 6 quarters it ranged from $10.2M (Q1 2025) to $27.3M (Q3 2026).
| Quarter | ZORYVE cream 0.15% revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $27.3M | +13% | +44% |
| Q2 2026 | $24.2M | +11% | +66% |
| Q1 2026 | $21.7M | +15% | +113% |
| Q3 2025 | $18.9M | +30% | — |
| Q2 2025 | $14.6M | +43% | — |
| Q1 2025 | $10.2M | — | — |
Q3 2026 at a glance
Arcutis Biotherapeutics, Q3 2026: revenue $144M (+45% year over year), operating margin 6.6%, net earnings $8.8M, operating cash flow $18.9M. The chart follows the revenue to costs, profit and cash.
Questions
What is Arcutis Biotherapeutics' ZORYVE cream 0.15% revenue?
Arcutis Biotherapeutics' ZORYVE cream 0.15% revenue was $27.3M in Q3 2026 (third quarter 2026), +13% from Q2 2026.
How has Arcutis Biotherapeutics' ZORYVE cream 0.15% revenue changed?
Over the last 6 quarters it ranged from $10.2M (Q1 2025) to $27.3M (Q3 2026).
Q3 2026 results → · How Arcutis Biotherapeutics makes money →